The purpose of this study was to assess the effect of DT56a (Femarelle), a selective estrogen receptor modulator, on platelet function in normal and thrombophilic women being treated for severe menopausal symptoms.
The Platelet Function Analyzer-100 (PFA-100) was used to asses platelet reactivity at baseline and after 8 weeks of treatment with Femarelle (644 mg/d in divided doses) in 25 symptomatic postmenopausal women with normal clotting times and seven symptomatic women with shortened clotting times (<61 s). The PFA-100 measure of closure time is considered equal to clotting time in assessing clotting function and platelet adhesion, aggregation, and blood coagulation factors. Closure times were measured after 3 and 8 weeks in all participants and at 1 year in the women with shortened clotting times. The nonparametric Wilcoxon signed rank test was used to assess the changes between baseline and each of the three subsequent measurements.
Pretreatment study of all seven women with shortened closure times confirmed abnormalities associated with thrombophilia: four women were heterozygous for the factor V Leiden gene mutation, one was heterozygous for the prothrombin gene mutation, one was found to have protein S deficiency, and one had increased anticardiolipin antibodies. All participants reported improved symptoms during the treatment period. No significant change in closure times was found in the normally clotting participants after 3 or 8 weeks of Femarelle therapy (P > 0.26). No significant change in closure time was seen in the seven thrombophilic women after 3 or 8 weeks or 1 year of Femarelle treatment (P > 0.26). The regression curve for measures over time was not significant (P = 0.26).
Femarelle, whose active ingredient is DT56a, did not adversely affect platelet reactivity as measured by PFA closure times in symptomatic thrombophilic postmenopausal women or normal controls. Femarelle, a novel selective estrogen receptor modulator that inhibits menopausal symptoms without thrombogenicity, may offer a new clinical choice for therapy of symptomatic postmenopausal women.
From the 1Department of Obstetrics and Gynecology, NYU Interdisciplinary Program in Menopausal Medicine, New York University School of Medicine, New York, NY; 2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; 3Department of Medicine, NYU Interdisciplinary Program in Menopausal Medicine, New York University School of Medicine, New York, NY; and 4Department of Obstetrics and Gynecology, The Sheba Medical Center, Ramat Gan, Sackler Faculty of Medicine, Tel Aviv, Israel.
Received April 28, 2010; revised and accepted July 6, 2010.
Financial disclosure/conflicts of interest: Israel Yoles-medical director of Secure Pharmaceuticals Ltd. Richard Nachtigall, Frederick Naftolin, and Lila Nachtigall-volunteer members of Secure Pharmaceuticals Advisory Board. Secure Pharmaceuticals supplied the Femarelle capsules for the study.
Address correspondence to: Lila E. Nachtigall, MD, New York University School of Medicine, Department of Obstetrics and Gynecology, 251 East 33rd Street, 5th Floor, New York, NY 10016. E-mail: doctorlila@Gmail.com